We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




System Offers Both Morphology Preservation and Biomolecule Stabilization

By LabMedica International staff writers
Posted on 02 Feb 2009
An integrated laboratory system for sample fixation, stabilization, and purification is available. More...
The system allows scientists to perform histology, immunohistochemistry, and stabilized nucleic acid extractions from one sample without compromising workflow.

The system has two components: a tissue container and tissue kits. The dual-chambered container is prefilled with two reagents: a tissue fixative for fast penetration and fixation, and a tissue stabilizer for storage and transport. The fixation process uses a standard histocasette with a fixative that is an alternative to formalin and is stopped when the sample is transferred into the stabilizer. Fixation time is standardized at two to four hours.

The sample remains stable in the tissue stabilizer for transport and storage prior to processing. The tissue can then be paraffin embedded and processed in pathology workflows. After the tissue sample has been stabilized in tissue containers (and optionally paraffin embedded), ribonucleic acid (RNA), micro (mi)RNA, and DNA can be purified using tissue kits.

Laboratories working with human and animal tissue need to conduct a variety of analyses on limited sample materials. The recognized standard for preserving tissue morphology is formalin fixation/paraffin embedding (FFPE). This method provides excellent results for morphological studies, but it does not preserve biomolecules. As a result, the DNA, RNA, and miRNA molecules degrade, preventing the complete analysis required. This would hinder applications such as the development of diagnostics and therapeutics, biomarker discovery, and case-controlled and population-based clinical studies.

The technology, called the PAXgene tissue system, is the newest addition to Qiagen's (Frankfurt, Germany) suite of tissue management technologies. The suite includes integrated products that standardize all steps of the workflow, starting with archived or prospectively collected tissues and ending with data analysis. This ensures comparability and reproducibility of data from laboratory to laboratory.

Qiagen is a global provider of sample and assay technologies. Sample technologies are used to isolate and process nucleic acids and proteins from biologic samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutic, and biotechnology companies.

Related Links:

Qiagen




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.